Genitourinary Cancer

The Genitourinary Tumors Program at the Gill Center is one of only a handful of its kind in the country. Over the last decade, the program has become known for exceptional clinical care – particularly surgical expertise – and notable scientifc advances in understanding the molecular abnormalities of these cancers.

Surgical Expertise

Pediatric genitourinary cancers are uncommon, accounting for just 10% of all childhood cancers. At the Gill Center, our medical team treats every type of genitourinary cancer, including germ cell tumor (GCT), Wilms tumor and other cancers arising in the kidney, ureter, testis, ovary and urinary bladder. 

Each month a team of specialists, including urologists, pathologists, general surgeons, radiologists and others, convene to develop and review treatment plans for new and existing patients. The most common treatment is a combination of surgery and chemotherapy. Given the prominence of surgery in these treatment plans, our staff intentionally pursues advances in non-invasive surgery. For example:  

  • In 2012, our team published a paper in the Journal of Endourology on the successful use of robot-assisted laparoscopic retroperitoneal lymph node dissection in adolescents with paratesticular rhabdomyosarcoma and testicular germ-cell tumors (T-GCT). 

Program Highlights

  • It offers exceptional surgical expertise in clinical care and international leadership in GCT research.  
  • Dr. James Amatruda is Chair of the Children’s Oncology Group Germ Cell Tumor Biology Committee (2009-present).  
  • To support groundbreaking research, tissue from more than 90% of removed tumors is banked for ongoing research studies at UT Southwestern and elsewhere.  
  • Clinical program leadership by Dr. Jon Wickiser, Director of Oncology in the Gill Center. 


Contact Cancer and Blood Disorders


Contact Cancer and Blood Disorders at Legacy


Contact the Cancer and Blood Disorders Referral Coordinator